Welcome to our dedicated page for Oragenics news (Ticker: OGEN), a resource for investors and traders seeking the latest updates and insights on Oragenics stock.
Oragenics Inc. (NYSE American: OGEN) is a publicly-traded biopharmaceutical company specializing in innovative, proprietary technologies aimed at improving human health. Based in Sarasota, Florida, Oragenics is renowned for its cutting-edge research and development in the fields of neurology and infectious diseases. The company’s core business revolves around the development of novel pharmaceutical treatments, including nasal delivery medications, which promise significant advancements in therapeutic efficacy and patient outcomes.
Oragenics’ flagship product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid. Designed to cross the blood-brain barrier effectively, ONP-002 targets mild Traumatic Brain Injury (mTBI), commonly known as concussion. The drug reduces swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. This revolutionary approach positions ONP-002 as a potential game-changer in treating brain injuries.
In addition to ONP-002, Oragenics boasts a diverse product pipeline, including therapies targeting Niemann-Pick Disease Type C (NPC) and other infectious diseases. The company is also recognized for its ProBiora3 technology, which is the foundation of products like evoraplus™—a unique probiotic mint that promotes oral health by supporting gums, freshening breath, and whitening teeth.
Recent achievements highlight Oragenics' relentless pursuit of excellence. The company is preparing to initiate a Phase II clinical trial for ONP-002, with advancements in drug formulation aimed at optimizing intranasal delivery. Collaborating with Avance Clinical Pty Ltd, Oragenics is focused on conducting this trial in emergency departments at level one trauma centers, ensuring robust and well-structured studies.
The leadership team at Oragenics, led by President Michael Redmond and Chief Medical Officer Dr. James Kelly, emphasizes the importance of partnerships and advanced research. Their dedication is reflected in Oragenics' preclinical studies, which have shown significant improvements in molecular and behavioral outcomes following brain injury. The company's innovative approach to intranasal delivery as nanoparticles has further enhanced brain exposure and metabolism.
Oragenics' commitment to addressing unmet medical needs, such as concussions—which affect millions globally each year—has positioned the company as a pivotal player in the biopharmaceutical industry. Through continuous innovation and strategic collaborations, Oragenics aims to provide effective treatments for neurological disorders and improve patient outcomes worldwide.
For more information, visit www.oragenics.com.
Oragenics, Inc. (NYSE American: OGEN) has announced that CEO Kim Murphy will participate in the World Vaccine Congress in Washington, D.C., from April 3-6, 2023. The focus will be on the company's lead COVID-19 intranasal vaccine candidate, NT-CoV2-1, which has shown promising safety and immunogenicity results, paving the way for upcoming Phase 1 clinical trials. Oragenics recently entered a global license agreement with Inspirevax Inc. for a novel adjuvant, BDX301, to enhance NT-CoV2-1. This intranasal vaccine aims to provide advantages over injectable vaccines, including targeting mucosal immunity.
Oragenics, Inc. (NYSE American: OGEN) has reported positive results from third-party lab tests on its lantibiotics platform, targeting antibiotic-resistant infections. The tests showed that strains of Staphylococcus aureus (MRSA) and Enterococci (VRE) remain sensitive to Oragenics' compounds, despite resistance to standard therapies. This collaboration with Linnaeus Bioscience Inc. reinforces the efficacy of lantibiotics in combating serious infections. With over 2.8 million resistant infections annually in the U.S., Oragenics is focused on meeting this need through innovative antibiotic development.
Oragenics, Inc. (NYSE American: OGEN) has appointed Janet Huffman as Chief Financial Officer, effective March 7, 2023. With over 12 years of experience in financial leadership in healthcare, Huffman's expertise in capital raising and M&A will be crucial for Oragenics' development plans. She previously served as CFO of TRxADE HEALTH and was integral in the merger of Banyan Pediatric Care Centers. Huffman aims to enhance stakeholder value through strategic financial management. Oragenics focuses on combating infectious diseases, particularly with its intranasal COVID-19 vaccine candidate, NT-CoV2-1, leveraging research from the NIH.
Oragenics, Inc. (AMEX: OGEN) has entered an exclusive global licensing agreement with Inspirevax Inc. for the development of NT-CoV2-1, its lead intranasal COVID-19 vaccine candidate, utilizing Inspirevax's BDX301 adjuvant. This partnership establishes a Joint Development Committee to oversee collaborative efforts. Oragenics will be responsible for milestone and royalty payments, with potential for future intranasal vaccine developments. The agreement aims to address unmet medical needs. In December 2022, Oragenics reported no toxicity from prior studies, suggesting a favorable safety profile for NT-CoV2-1.
Oragenics, Inc. (NYSE American: OGEN) announced that it has regained compliance with NYSE American’s continued listing standards as of
Oragenics, Inc. (NYSE American: OGEN) announced a 1-for-60 reverse stock split approved by its Board on
FAQ
What is the current stock price of Oragenics (OGEN)?
What is the market cap of Oragenics (OGEN)?
What does Oragenics Inc. specialize in?
What is ONP-002?
What is the ProBiora3 technology?
What recent achievements has Oragenics made?
Who are key leaders at Oragenics?
What is the significance of intranasal delivery for ONP-002?
How does ONP-002 impact brain injury treatment?
What are the potential benefits of ONP-002?
What are common causes of concussions that ONP-002 aims to treat?
Where can I find more information about Oragenics?
